Race as a Proxy for Genetic Variation in Heart Failure

种族作为心力衰竭遗传变异的代表

• 批准号: 6995027
• 负责人: Raegan Winston Durant
• 金额: $ 5.35万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-22 至 2006-08-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6995027
• 关键词: African American; antihypertensive agents; behavioral /social science research tag; caucasian American; clinical research; decision making; focus groups; genetic susceptibility; health disparity; health services research tag; heart disorder chemotherapy; heart failure; heart pharmacology; human old age (65+); hydralazine; patient care personnel attitude; patient care personnel relations; pharmacogenetics; physicians; postdoctoral investigator; questionnaires; racial /ethnic difference; sugar alcohols; therapy compliance

DESCRIPTION (provided by applicant): The role of genetic variation in observed racial differences in heart failure morbidity and mortality are unknown. Clinical trial data suggests that African Americans with heart failure may benefit from a combination of hydralazine/isosorbide dinitrate previously thought to be ineffective in all populations. This discovery has led to the development of a hydralazine/isosorbide dinitrate combination, which may be approved for use exclusively in African Americans with heart failure. Physicians' perceptions on race and genetic variation and patient trust are likely to influence the implementation of any race-based therapies. While African Americans often place less trust in physicians, the underlying factors associated with racial differences in trust have not been fully elucidated. To determine the factors underlying racial differences in patient trust and to explore the use of race as a proxy for genetic variation in the treatment of heart failure, the applicant proposes a two-phase study. Phase I uses quantitative methods to analyze survey data on patient trust among African Americans and Caucasians. Phase II uses focus groups to explore physicians' perceptions of use of race as a proxy for genetic variation in the treatment of heart failure.

描述（由申请人提供）：遗传变异在观察到的心力衰竭发病率和死亡率的种族差异中的作用尚不清楚。临床试验数据表明，患有心力衰竭的非裔美国人可能会受益于肼苯哒嗪/硝酸异山梨酯的组合，此前人们认为这种组合对所有人群都无效。这一发现导致了肼苯哒嗪/硝酸异山梨酯组合的开发，该组合可能被批准专门用于患有心力衰竭的非裔美国人。医生对种族和遗传变异的看法以及患者的信任可能会影响任何基于种族的治疗的实施。虽然非裔美国人对医生的信任度往往较低，但与种族信任差异相关的潜在因素尚未完全阐明。为了确定患者信任方面的种族差异背后的因素，并探索在心力衰竭治疗中使用种族作为遗传变异的代表，申请人提出了一项两阶段研究。第一阶段使用定量方法来分析非裔美国人和白人之间患者信任度的调查数据。第二阶段利用焦点小组来探讨医生对在心力衰竭治疗中使用种族作为遗传变异指标的看法。